SCHEMBL4587607

SCHEMBL4587607

O=C(O)C(=O)CCCN1CCC(O[N+](=O)[O-])CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
CYP1A2 P05177 1/20 0.37
MAPK1 P28482 1/20 0.37
BCHE P06276 3/20 0.36
TMEM97 Q5BJF2 7/20 0.36
ADRA1D P25100 2/20 0.34
ADRA1A P35348 2/20 0.34
ADRA1B P35368 2/20 0.34
NPC1 O15118 1/20 0.34
MLNR O43193 1/20 0.34
NR1I2 O75469 1/20 0.34
EGFR P00533 1/20 0.34
LMNA P02545 1/20 0.34
ERBB2 P04626 1/20 0.34
FYN P06241 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4586997 0.96 KDM4E (0.40) KDM4ECYP2D6CYP2C19BCHETMEM97
SCHEMBL4585987 0.91 ALDH1A1 (0.35) KDM4ECYP2D6CYP2C19SMN1; SMN2CYP1A2
SCHEMBL5148816 0.81 GSR (0.35) KDM4ECYP2D6CYP2C19BCHETMEM97
SCHEMBL9330735 0.78 KEAP1 (0.39) SMN1; SMN2CHRM3
Fumaric Acid SCHEMBL9345668 0.78 CHRM3 (0.40) KDM4ECYP2D6CYP2C19BCHETMEM97
SCHEMBL5154489 0.78 SLC18A3 (0.38) KDM4ECYP2C19SMN1; SMN2TMEM97LMNA
Fumaric Acid SCHEMBL9345675 0.76 KCNH2 (0.43) BCHECHRM3KCNH2
SCHEMBL9330759 0.76 GNAO1 (0.50) CHRM3KCNH2
SCHEMBL4593885 0.76 SMN1; SMN2 (0.39) KDM4ECYP2D6CYP2C19SMN1; SMN2CYP1A2
SCHEMBL4594578 0.76 SMN1; SMN2 (0.39) KDM4ECYP2D6CYP2C19SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US claimed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP claimed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP claimed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO claimed
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US disclosed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP disclosed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP disclosed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 KDM4E 2405/4885CYP2D6 2903/4885CYP2C19 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.